Who We Are

HaemSTAR is a UK-wide network of passionate Clinical Haematology registrars and trainees. We aim to promote collaborative research in haematology across the UK, focusing on medical haematology.

HaemSTAR

HaemSTAR is an independent UK-wide network of registrars and trainees, interested in promoting and performing research in medical haematology. Our focus is on collaborative projects in medical haematology.

What is medical haematology?

Medical haematology is an all-encompassing term for the parts of haematology that are not primarily cancer. This includes looking after patients with serious clotting disorders, bleeding disorders, and red cell disorders. The speciality of transfusion transcends medicine. The disciplines within medical haematology can be listed as:

  • Haemostasis (bleeding problems)

  • Immunhaematology (autoimmune disorders such as ITP and TTP)

  • Obstetric haematology (haematological disorders of pregnancy)

  • Thrombosis (clotting problems)

  • Transfusion medicine

How we operate

A small committee manages a hub-and-spoke model covering over 25 regions in the United Kingdom. Each region has a haematology registrar, acting as a regional lead, that organises research activity at a local level.

We aim to promote research in medical haematology by:

  • Assisting outside studies: This increases patient recruitment to classical haematology trials.

  • Upscaling worthy local projects to the national scale: This increases the power and applicability of study results.

  • Providing Principle Investigator (PI) experience: This enables more haematologists in training to lead clinical research within their trusts.

  • Developing and leading our own studies: This creates chief investigators of the future.

  • Developing international collaborations to promote global haematology.

Our Funding

HaemSTAR is a registered charity (Charity Number: 1199224).

We are proud to work with a number of charitable, governmental and industry partners. We have received funding for our projects and educational events from the following sources:

  • AstraZeneca

  • Chugai Pharma UK

  • Dudley Leukaemia Unit Appeal Fund

  • Novartis

  • Octapharma

  • Sanofi

  • Scientific and Academic Coagulation Consortium (Katie Bolam Award)

  • Takeda

  • West Midlands NIHR LCRN

  • Sobi- Swedish Orphan Biovitrum AB

Authorship Policy

All publications that arise from HaemSTAR projects are authored on behalf of the group. As collaborators are involved at every stage of the project (design, execution and dissemination), we ask journals to provide all contributors with PubMed citable authorship. This is in line with the International Committee of Medical Journal Editors guidelines. An example can be found here.

In March 2022 we introduced a HaemSTAR Agreement of Authorship, which will be required of any project that involves significant input from the HaemSTAR network. We are happy to work with study leads to identify journals that have a record of delivering citable collaborative authorship.